Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Increased to Strong-Buy at Brookline Capital Management

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) was upgraded by stock analysts at Brookline Capital Management to a "strong-buy" rating in a research note issued on Wednesday,Zacks.com reports.

A number of other research analysts also recently issued reports on YMAB. BMO Capital Markets lowered their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, August 13th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Wedbush reissued an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Morgan Stanley dropped their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an "underweight" rating on the stock in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Y-mAbs Therapeutics has an average rating of "Buy" and a consensus price target of $20.89.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB traded up $0.24 during mid-day trading on Wednesday, reaching $10.54. The company had a trading volume of 272,544 shares, compared to its average volume of 326,164. The company has a market capitalization of $472.09 million, a price-to-earnings ratio of -19.52 and a beta of 0.61. The firm has a 50-day moving average price of $13.24 and a 200 day moving average price of $12.76. Y-mAbs Therapeutics has a 52 week low of $6.09 and a 52 week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. During the same period last year, the firm posted ($0.18) earnings per share. As a group, research analysts forecast that Y-mAbs Therapeutics will post -0.64 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Thomas Gad sold 30,000 shares of the firm's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now owns 67,681 shares of the company's stock, valued at $877,822.57. This trade represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 22.50% of the company's stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Barclays PLC raised its holdings in Y-mAbs Therapeutics by 433.4% during the third quarter. Barclays PLC now owns 69,222 shares of the company's stock valued at $910,000 after acquiring an additional 56,244 shares during the period. Empire Financial Management Company LLC purchased a new stake in shares of Y-mAbs Therapeutics during the third quarter worth about $210,000. Geode Capital Management LLC raised its stake in Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company's stock valued at $10,699,000 after purchasing an additional 47,846 shares during the period. State Street Corp lifted its holdings in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company's stock worth $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Finally, Caligan Partners LP lifted its holdings in Y-mAbs Therapeutics by 105.3% in the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company's stock worth $15,718,000 after purchasing an additional 613,175 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.